FDA Approves Sparsentan to Treat Focal Segmental Glomerulosclerosis by Madaline Spencer| Published on: Apr 16, 2026

https://checkrare.com/fda-approves-sparsentan-to-treat-focal-segmental-glomerulosclerosis/ The US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in patients with focal segmental glomerulosclerosis (FSGS). The indication includes adult and pediatric patients ages 8 years and older without nephrotic syndrome.